Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Advanced renal cell carcinoma (aRCC) is an aggressive form of kidney cancer in which malignant cells originating in the renal cortex spread beyond the kidney to distant organs or lymph nodes. According to Deng Li et al., 2025, clear cell renal cell carcinoma accounts for nearly 80% of primary kidney malignancies. Renal cell carcinoma represents about 2–3% of adult cancers globally. Current treatment approaches include immune checkpoint inhibitors, tyrosine kinase inhibitors, and combination immunotherapy regimens. Increasing research on targeted therapies, HIF-2α inhibitors, and biomarker-guided treatment is expanding the drug pipeline. According to the advanced renal cell carcinoma pipeline analysis by Expert Market Research, continuous clinical development and rising disease burden are expected to drive therapeutic innovation and pipeline growth in the coming years.
-
Major companies involved in the advanced renal cell carcinoma pipeline analysis include Exelixis, Jiangsu Hansoh Pharmaceutical Co., Ltd., and others.
-
Leading drugs currently in the pipeline include XL092 + Nivolumab, HS-10516 + Lenvatinib, NEO-811, and others.
-
The robust clinical development of immune checkpoint inhibitor combinations, next-generation tyrosine kinase inhibitors, and HIF-2α targeted therapies is accelerating treatment innovation, supported by expanding clinical trials and growing precision oncology strategies.
Report Coverage
The Advanced Renal Cell Carcinoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into advanced renal cell carcinoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for advanced renal cell carcinoma. The advanced renal cell carcinoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The advanced renal cell carcinoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with advanced renal cell carcinoma treatment guidelines to ensure optimal care practices.
The assessment part will include detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to advanced renal cell carcinoma.
Read more about this report - Request a Free Sample
Advanced Renal Cell Carcinoma Pipeline Outlook
Advanced renal cell carcinoma (RCC) is a highly aggressive kidney cancer arising from malignant cells in the renal cortex that grow uncontrollably, often invading nearby tissues and metastasizing to distant organs. It frequently develops due to genetic mutations, environmental exposures, or pre-existing kidney disorders, which trigger abnormal cell proliferation and tumor formation. Advanced RCC is often diagnosed at later stages, complicating treatment and increasing the risk of systemic spread and organ dysfunction.
Advanced renal cell carcinoma treatments involve targeted therapies, immune checkpoint inhibitors, and combination regimens designed to inhibit tumor growth, boost the immune response, and extend patient survival. Treatment choice depends on prior therapies and disease progression. In December 2023, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) for patients who progressed after a PD-1 or PD-L1 inhibitor and a VEGF tyrosine kinase inhibitor. The LITESPARK-005 trial demonstrated significant improvement in progression-free survival and favorable tolerability, establishing belzutifan as a promising advancement in the RCC drug pipeline.
Advanced Renal Cell Carcinoma Epidemiology
The global burden of renal cell carcinoma (RCC) is rising. According to Deng Li et al., 2025, clear cell RCC accounts for approximately 80% of primary kidney malignancies. As per Sandeep Anand Padala et al., 2020, RCC represents about 2% of global cancer diagnoses and deaths, with an increasing incidence projected worldwide. According to Merck & Co., Inc., in the United States, an estimated 81,610 new RCC cases and 14,390 deaths occur annually, predominantly in men aged 65–74. As per Cécile Freymann et al., 2026, France reported 14,700 new cases in 2020. According to Sonia Gupta, et al., 2024, India’s incidence is 2 per 100,000 in males and 1 per 100,000 in females.
Advanced Renal Cell Carcinoma – Pipeline Therapeutic Assessment
This section of the report covers the analysis of advanced renal cell carcinoma drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The advanced renal cell carcinoma pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Peptides
- Polymers
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Advanced Renal Cell Carcinoma Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I, with 47%, covers a major share of the total advanced renal cell carcinoma clinical trials, driven by a high number of early clinical candidates and novel mechanism exploration. Phase II holds 42%, reflecting strong efficacy evaluation and dose optimization. Phase III contributes 9%, supported by advanced clinical validation and regulatory progress. These factors collectively strengthen market growth and therapeutic options.
Advanced Renal Cell Carcinoma Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the advanced renal cell carcinoma pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The advanced renal cell carcinoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for advanced renal cell carcinoma. Targeted therapies are emerging as a promising approach in the advanced renal cell carcinoma (RCC) pipeline. For instance, WELIREG® (belzutifan), a first-in-class oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, is being evaluated in combination with LENVIMA® (lenvatinib), a multi-targeted tyrosine kinase inhibitor. This combination demonstrated significant improvement in progression-free survival compared to cabozantinib, offering a new option for patients with RCC who are resistant to prior PD-1/PD-L1 therapies.
Advanced Renal Cell Carcinoma Clinical Trials – Key Players
The EMR report for the advanced renal cell carcinoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed advanced renal cell carcinoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in advanced renal cell carcinoma clinical trials:
- Exelixis
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
- Neomorph, Inc.
- Imbioray (Hangzhou) Biomedicine Co., Ltd.
- Daiichi Sankyo
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Pfizer
- Bristol-Myers Squibb
- Merck Sharp & Dohme LLC
- Eisai Inc.
- Osel, Inc.
- Arcus Biosciences, Inc.
Advanced Renal Cell Carcinoma – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for advanced renal cell carcinoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of advanced renal cell carcinoma drug candidates.
Drug: XL092 + Nivolumab
Zanzalintinib (XL092) is being evaluated in a Phase 3 clinical trial sponsored by Exelixis for the treatment of advanced or metastatic non-clear cell renal cell carcinoma. The study is comparing the oral tyrosine kinase inhibitor zanzalintinib in combination with the intravenous immune checkpoint inhibitor Nivolumab against Sunitinib in previously untreated patients. Zanzalintinib inhibits multiple receptor tyrosine kinases, including VEGFR, MET, AXL, and MER, which are tumor angiogenesis, metastasis, and resistance to immunotherapy. The trial examines the combination of efficacy and safety in improving clinical outcomes. The study started in January 2023, is expecting primary completion in July 2025, and is continuing until June 2028.
Drug: HS-10516 + Lenvatinib
HS-10516 is an oral small-molecule HIF-2α inhibitor that modulates the hypoxia-inducible factor pathway involved in tumor growth and angiogenesis in renal cancers. The drug is being evaluated in combination with Lenvatinib, an oral multi-kinase inhibitor targeting VEGFR, FGFR, and other angiogenic signaling pathways. Jiangsu Hansoh Pharmaceutical Co., Ltd. is conducting a Phase Ib/II multicenter, open-label study to examine the safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of the combination in patients with advanced clear cell renal cell carcinoma who have progressed after prior therapy. The trial is enrolling participants and is expected to reach primary completion in July 2027, with overall study completion anticipated by July 2028.
Drug: NEO-811
NEO-811 is being evaluated in an open-label Phase 1/2 clinical trial sponsored by Neomorph, Inc. for patients with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study examines the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of this investigational therapy. NEO-811 is a first-in-class molecular glue degrader administered systemically that selectively induces degradation of a disease-driving protein and blocks a key signaling pathway involved in tumor progression in ccRCC. The dose-escalation and expansion study is currently recruiting participants and is expected to reach primary completion in January 2027, with overall study completion anticipated in September 2027.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Advanced Renal Cell Carcinoma Pipeline Insight Report
- Which companies/institutions are leading the advanced renal cell carcinoma drug development?
- Which company is leading the advanced renal cell carcinoma pipeline development activities?
- What is the current advanced renal cell carcinoma commercial assessment?
- What are the opportunities and challenges present in the advanced renal cell carcinoma pipeline landscape?
- What is the efficacy and safety profile of advanced renal cell carcinoma pipeline drugs?
- Which company is conducting major trials for advanced renal cell carcinoma drugs?
- Which companies/institutions are involved in advanced renal cell carcinoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in advanced renal cell carcinoma?
Reasons To Buy This Report
The Advanced Renal Cell Carcinoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for advanced renal cell carcinoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into advanced renal cell carcinoma collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share